High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: High-dose therapy with supporting autologous stem-cell transplantation remains a controversial treatment for cancer. In multiple myeloma, first-line regimens incorporating high-dose therapy yield higher remission rates than do conventional-dose treatments, but evidence that this translates into improved survival is limited. METHODS: In this multicenter study, the Medical Research Council Myeloma VII Trial, we randomly assigned 407 patients with previously untreated multiple myeloma who were younger than 65 years of age to receive either standard conventional-dose combination chemotherapy or high-dose therapy and an autologous stem-cell transplant. RESULTS: Among the 401 patients who could be evaluated, the rates of complete response were higher in the intensive-therapy group than in the standard-therapy group (44 percent vs. 8 percent, P<0.001). The rates of partial response were similar (42 percent and 40 percent, respectively; P=0.72), and the rates of minimal response were lower in the intensive-therapy group than in the standard-therapy group (3 percent vs. 18 percent, P<0.001). Intention-to-treat analysis showed a higher rate of overall survival (P=0.04 by the log-rank test) and progression-free survival (P<0.001) in the intensive-therapy group than in the standard-therapy group. As compared with standard therapy, intensive treatment increased median survival by almost 1 year (54.1 months [95 percent confidence interval, 44.9 to 65.2] vs. 42.3 months [95 percent confidence interval, 33.1 to 51.6]). There was a trend toward a greater survival benefit in the group of patients with a poor prognosis, as defined by a high beta2-microglobulin level (more than 8 mg per liter). CONCLUSIONS: High-dose therapy with autologous stem-cell rescue is an effective first-line treatment for patients with multiple myeloma who are younger than 65 years of age.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ASCT improves median OS in multiple myeloma by approximately 12 months.125–128”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [126]
Citations
Cites
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
BladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Fermand, J.-P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., Macro, M., Pertuiset, E., Dreyfus, F., Mariette, X., et al. (1998) · Blood · doi:10.1182/blood.v92.9.3131 · Cited by 542
Barlogie, B., Jagannath, S., Vesole, D. H., Naucke, S., Cheson, B., Mattox, S., Bracy, D., Salmon, S., Jacobson, J., Crowley, J., et al. (1997) · Blood · doi:10.1182/blood.v89.3.789 · Cited by 541
HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMA
MCELWAIN, T. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90739-0 · Cited by 510
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., et al. (1999) · Blood · doi:10.1182/blood.v93.1.55.401k04_55_65 · Cited by 502
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., et al. (1999) · Blood · doi:10.1182/blood.v93.1.55 · Cited by 472
Facon, T., Avet-Loiseau, H., Guillerm, G., Moreau, P., Geneviève, F., Zandecki, M., Laı̈, J.-L., Leleu, X., Jouet, J.-P., Bauters, F., et al. (2001) · Blood · doi:10.1182/blood.v97.6.1566 · Cited by 312
Lenhoff, S., Hjorth, M., Holmberg, E. C., Turesson, I., Westin, J., Nielsen, J. L., Wislöff, F., Brinch, L., Carlson, K. E., Carlsson, M. S., et al. (2000) · PubMed · doi:10.1182/blood.v95.1.7 · Cited by 310
Research works printed but not linked: 7
- Morgan G, Selby P. Myeloma. In: Souhami R, Tannock I, Hohenberger P, Horiot J-C, eds. Oxford textbook of oncology. 2nd ed. Vol. 2. Oxford, England: Oxford University Press, 2001:2419-55.
- Lenhoff S, 2000, Blood, 95, 7
- Fermand J-P, 1999, Blood, 94, 396a
- Review manager (RevMan), version 4.1. Oxford, England: Cochrane Collaboration, 2000.
- Blade J, 2001, Blood, 98, 815a
- Segeren CM, 2001, Blood, 98, 815a
- Fermand J-P, 2001, Blood, 98, 815a
Cited by
Items 501–600 of 1,000
Shah, G. L., Winn, A. N., Lin, P., Klein, A. K., Sprague, K., Smith, H. P., Buchsbaum, R. J., Cohen, J. T., Miller, K. B., Comenzo, R. L., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.05.013 · Cited by 40
“Induction chemotherapy followed by high-dose melphalan with Auto HSCT is standard of care for the treatment of MM in younger patients, with median overall survival (OS) prolonged by at least 12 months with the use of Auto HSCT [5,6].”
Sanchez, L. J., Sylvester, M. J., Parrondo, R. D., Mariotti, V., Eloy, J. A., & Chang, V. T.-S. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.03.012 · Cited by 37
Bortezomib: Proteasome Inhibition as an Effective Anticancer Therapy
Richardson, P. G. G., & Mitsiades, C. S. (2005) · Future Oncology · doi:10.1517/14796694.1.2.161 · Cited by 40
Lin, B. K., Catley, L. P., LeBlanc, R., Mitsiades, C. S., Burger, R., Tai, Y., Podar, K., Wartmann, M., Chauhan, D., Griffin, J. D., et al. (2004) · Blood · doi:10.1182/blood-2004-06-2499 · Cited by 37
Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma
Anderson, L. D., Cook, D. R., Yamamoto, T. N., Berger, C., Maloney, D. G., & Riddell, S. R. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1009-3 · Cited by 37
“Survival can be prolonged with autologous stem cell transplantation (SCT) and other therapy combinations [1–5], but the disease recurs in almost all patients.”
BackgroundStraka, C., Liebisch, P., Salwender, H. J., Hennemann, B., Metzner, B., Knop, S. T., Adler-Reichel, S., Gerecke, C., Wandt, H., Bentz, M., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.151860 · Cited by 41
Induction Therapy for Newly Diagnosed Multiple Myeloma
Paul, B. A., Lipe, B. C., Ocio, E. M., & Usmani, S. Z. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238527 · Cited by 37
Giralt, S., Costa, L. J., Maloney, D. G., Krishnan, A. Y., Fei, M., Antin, J. H., Brunstein, C. G., Geller, N. L., Goodman, S. A., Hari, P., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.11.018 · Cited by 37
Jackson, G. H., Davies, F. E., Pawlyn, C., Cairns, D. A., Striha, A., Collett, C., Waterhouse, A., Jones, J. R., Kishore, B., Garg, M. K., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.247130 · Cited by 40
Self-citationRecent Advances in the Treatment of Patients with Multiple Myeloma
Legarda, M., Cejalvo, M. J., & de la Rubia, J. (2020) · Cancers · doi:10.3390/cancers12123576 · Cited by 39
Outpatient Autologous Stem Cell Transplantation for Patients With Myeloma
Paul, T. M., Liu, S. V., Chong, E. A., Luger, S. M., Porter, D. L., Schuster, S. J., Tsai, D. E., Nasta, S. D., Loren, A. W., Frey, N. V., et al. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.05.006 · Cited by 38
“High-dose melphalan with autologous stem cell transplant (ASCT) is a standard component of multiple myeloma treatment because of its demonstrated survival advantage over standard dose chemotherapy (1,2).”
BackgroundMethodInfluentialMartino, M. V., Montanari, M., Ferrara, F., Ciceri, F., Scortechini, I., Palmieri, S., Marktel, S., Cimminiello, M., Messina, G., Irrera, G., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.03.027 · Cited by 38
“(2) The integrity of the work and identification of the author, copyright owner, and publisher must be preserved in any copy.”
BackgroundPalumbo, A., Falco, P., Ambrosini, M. T., Petrucci, M. T., Musto, P., Caravita, T., Pregno, P., Bertola, A., Cavallo, F., Ciccone, G., et al. (2005) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2005.00533.x · Cited by 38
Abdelkefi, A., Torjman, L., Romdhane, N. B., Ladeb, S., Omri, H. E., Othman, T. B., Elloumi, M., Bellaj, H., Lakhal, A., Jeddi, R., et al. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705050 · Cited by 37
RetractedTargeted therapy in haematological malignancies
Hamilton, A., Gallipoli, P., Nicholson, E., & Holyoake, T. L. (2009) · The Journal of Pathology · doi:10.1002/path.2669 · Cited by 45
“In MM, the use of high-dose chemotherapy followed by autologous stem cell rescue has changed the management and dramatically improved outcome, with a significant increase in median survival [157,158].”
BackgroundPosttransplant maintenance therapy in multiple myeloma: the changing landscape
Sengsayadeth, S. M., Malard, F., Savani, B. N., Garderet, L., & Mohty, M. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.23 · Cited by 39
Kazandjian, D. G., Mo, C. C., Landgren, O., & Richardson, P. G. G. (2020) · British Journal of Haematology · doi:10.1111/bjh.16764 · Cited by 36
ANKHD1 regulates cell cycle progression and proliferation in multiple myeloma cells
Dhyani, A., Duarte, A. S. S., Machado‐Neto, J. A., Favaro, P. M. B., Ortega, M. M., & Saad, S. T. O. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.10.037 · Cited by 39
“Current therapies for the disease include chemotherapy with or without stem cell transplantation, glucocorticosteroids, thalidomide, the proteosome inhibitor bortezomib, and combinations of these agents [6–8].”
BackgroundSivaraj, D., Green, M. M., Li, Z., Sung, A. D., Sarantopoulos, S., Kang, Y., Long, G. D., Horwitz, M. E., Lopez, R. D., Sullivan, K. M., et al. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.11.010 · Cited by 37
Targeted Therapy in Multiple Myeloma
Chng, W. J., Lau, L. G., Yusof, N., & Mow, B. M. F. (2005) · Cancer Control · doi:10.1177/107327480501200204 · Cited by 39
“52 Mechanism of Action: The immunomodulatory effects of CC-5013 and CC-4047 are believed to be due to their ability to (1) decrease the levels of TNF-α by enhancing the degradation of its mRNA or by inhibiting its synthesis by monocytes,53 (2) stimulate the activation and expansion of T cells by providing the costimul…”
BackgroundBone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents
Cibeira, M. T., Rozman, M., Segarra, M., Lozano, E., Rosiñol, L., Cid, M. C., Filella, X., & Bladé, J. (2008) · Cytokine · doi:10.1016/j.cyto.2007.11.017 · Cited by 36
Cavo, M., Terragna, C., Renzulli, M., Zamagni, E., Tosi, P., Testoni, N., Nicci, C., Cangini, D., Tacchetti, P., Grafone, T., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7506 · Cited by 35
The evolution and impact of therapy in multiple myeloma
Laubach, J. P., Richardson, P. G. G., & Anderson, K. C. (2010) · Medical Oncology · doi:10.1007/s12032-010-9442-2 · Cited by 40
“motherapy followed by high-dose melphalan and ASCT [36].”
Novel Strategies for Immunotherapy in Multiple Myeloma: Previous Experience and Future Directions
Danylesko, I., Beider, K., Shimoni, A., & Nagler, A. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/753407 · Cited by 40
Mark, T. M., Reid, W. L., Niesvizky, R., Gergis, U. S., Pearse, R. N., Mayer, S. A., Greenberg, J., Coleman, M., van Besien, K., & Shore, T. B. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.02.013 · Cited by 34
“INTRODUCTION High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has been a mainstay of therapy for the treatment of multiple myeloma (MM) since randomized trials in the 1990s showed superiority to conventional chemotherapy [1,2].”
BackgroundCosta, L. J., Kramer, C., Hogan, K. R., Butcher, C., Littleton, A., Shoptaw, K. B., Kang, Y., & Stuart, R. K. (2012) · Transfusion · doi:10.1111/j.1537-2995.2012.03579.x · Cited by 40
Winn, A. N., Shah, G. L., Cohen, J. T., Lin, P., & Parsons, S. K. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv139 · Cited by 34
“Hematopoietic stem cell transplant (HSCT) is considered the preferred treatment for eligible patients with multiple myeloma (MM) (1,2).”
BackgroundKim, S. J., Kım, K., Kim, B., Jo, D., Kang, H. J., Kim, J. S., Mun, Y., Kim, C. S., Sohn, S. K., Eom, H., et al. (2009) · Acta Haematologica · doi:10.1159/000253027 · Cited by 34
“An association between response to therapy and long-term outcomes has been suggested, with the quality of response also being reported as an important prognostic factor in MM [ ,”
BackgroundBortezomib in multiple myeloma
Terpos, E., Ρούσσου, Μ., & Dimopoulos, M. A. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.5.639 · Cited by 37
“HDT plus SCT was shown to increase survival significantly compared with conventional chemotherapy [8,9] , but not all trials confirmed this survival advantage [10,11] .”
BackgroundDurie, B. G. M. (2005) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2005.n.045 · Cited by 39
Bock, F. M., Lu, G. G., Srour, S. A., Gaballa, S. R., Lin, H. Y., Baladandayuthapani, V., Honhar, M., Stich, M., Shah, N. D., Bashir, Q., et al. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.09.003 · Cited by 35
“Historically, the PFS after auto-HCT for multiple myeloma patients receiving an auto-HCT in first remission without maintenance is 24–30 months [27, 28] and 41–46 months with maintenance therapy with lenalidomide [29, 30].”
BackgroundClinical outcomes with intensive therapy for patients with primary resistant multiple myeloma
Alexanian, R., Weber, D., Delasalle, K. B., Handy, B. C., Champlin, R., & Giralt, S. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704562 · Cited by 35
The adverse prognostic impact of advanced age in multiple myeloma
Mileshkin, L., & Prince, H. M. (2005) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500085024 · Cited by 36
“It is now well established that the use of HDT supported by AuSCT is superior therapy to the use of conventional-dose chemotherapy alone in terms of CR rate, EFS and OS for patients up to the age of 65 years [14,15].”
BackgroundMethodResultState of the art therapy in multiple myeloma and future perspectives
Denz, U., Haas, P. S., Wäsch, R., Einsele, H., & Engelhardt, M. M. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.11.040 · Cited by 43
Genetic variations in multiple myeloma II: association with effect of treatment
Vangsted, A. J., Klausen, T. W., & Vogel, U. B. (2011) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2011.01696.x · Cited by 36
Pomalidomide therapy for myeloma
Schey, S., & Ramasamy, K. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.567265 · Cited by 34
“It is licensed by the EMEA (European Medicines Agency) for myeloma in combination with prednisone for patients older than 65 years who are not eligible for ASCT and cannot be treated with thalidomide or bortezomib.”
BackgroundVarmavuo, V., Mäntymaa, P., Silvennoinen, R. H., Nousiainen, T., Kuittinen, T., & Jantunen, E. (2012) · Transfusion · doi:10.1111/j.1537-2995.2012.03848.x · Cited by 37
Chakraborty, R., Muchtar, E., Kumar, S. K., Buadi, F. K., Dingli, D., Dispenzieri, A. A., Hayman, S. R., Hogan, W. J., Kapoor, P., Lacy, M. Q., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.214 · Cited by 37
Maffini, E., Storer, B. E., Sandmaier, B. M., Bruno, B., Sahebi, F., Shizuru, J. A., Chauncey, T. R., Hari, P., Lange, T., Pulsipher, M. A., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.200253 · Cited by 35
Chaudhary, L. N., Awan, F. T., Cumpston, A., Leadmon, S., Watkins, K., Tse, W. W., Craig, M., & Hamadani, M. (2013) · Journal of Clinical Apheresis · doi:10.1002/jca.21280 · Cited by 33
“High dose therapy (HDT) and autologous hematopoietic cell transplantation (auto-HCT) is a key therapeutic modality in the management of transplant eligible multiple myeloma (MM) patients [1,2].”
BackgroundMcCann, K. J., Godeseth, R., Chudley, L., Mander, A., Genova, G. D., Lloyd-Evans, P., Kerr, J. P., Malykh, V., Jenner, M. W., Orchard, K. H., et al. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1703-7 · Cited by 33
Kumar, S. K., Pérez, W. S., Zhang, M., Ballen, K. K., Bashey, A., To, L. B., Bredeson, C., Cairo, M. S., Elfenbein, G. J., Freytes, C. O., et al. (2008) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.07.011 · Cited by 36
“Autologous stem cell transplantation (ASCT) has been shown to provide a survival advantage compared to conventional chemotherapy.(11,12) Given the differences in the clinical characteristics, it is not clear how the results of ASCT in this group of patients compare with those with secretory disease.”
Advance care planning among hematopoietic cell transplant patients and bereaved caregivers
Loggers, E. T., Lee, S. J., Chilson, K., Back, A. L., Block, S. D., & Loberiza, F. R. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.152 · Cited by 33
Fenk, R. R., Hieronimus, N., Steidl, U. U., Bruns, I., Graef, T. T., Zohren, F., Ruf, L., Haas, R. R., & Kobbe, G. (2006) · Experimental Hematology · doi:10.1016/j.exphem.2006.06.002 · Cited by 33
Richardson, P. G. G., Laubach, J. P., Munshi, N. C., & Anderson, K. C. (2014) · Hematology · doi:10.1182/asheducation-2014.1.255 · Cited by 35
Bensinger, W., Becker, P. S., Gooley, T. A., Chauncey, T. R., Maloney, D. G., Gopal, A. K., Green, D. J., Press, O. W., Lill, M., Ifthikharuddin, J. J., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.211 · Cited by 33
Jain, T., Sonbol, M. B., Firwana, B., Kolla, K. R., Almader‐Douglas, D., Palmer, J. M., & Fonseca, R. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.09.021 · Cited by 34
Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m2)
Palumbo, A., Bringhen, S., Bertola, A., Cavallo, F., Falco, P., Massaia, M., Bruno, B., Rus, C. P., Barbui, A. M., Caravita, T., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403196 · Cited by 34
Ho, J., Yang, L., Banihashemi, B., Martin, L., Halpenny, M., Atkins, H. L., Sabloff, M., McDiarmid, S. A., Huebsch, L. B., Bence‐Bruckler, I., et al. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.318 · Cited by 38
Barlogie, B., Bolejack, V., Schell, M. J., & Crowley, J. J. (2010) · Annals of Hematology · doi:10.1007/s00277-010-1130-y · Cited by 38
Cibeira, M. T., Rosiñol, L., Ramiro, L., Esteve, J., Torrebadell, M., & Bladé, J. (2006) · European Journal Of Haematology · doi:10.1111/j.0902-4441.2006.t01-1-ejh2783.x · Cited by 35
Stem cell transplantation in multiple myeloma (0, 1, or 2)
Harousseau, J. (2005) · Current Opinion in Oncology · doi:10.1097/01.cco.0000152978.32304.37 · Cited by 34
Dispenzieri, A. A., Wiseman, G. A., Lacy, M. Q., Hayman, S. R., Kumar, S. K., Buadi, F. K., Dingli, D., Laumann, K. M., Allred, J., Geyer, S. M., et al. (2010) · American Journal of Hematology · doi:10.1002/ajh.21696 · Cited by 35
Wang, S., Tricot, G. J. K., Shi, L., Xiong, W., Zeng, Z., Xu, H., Zangari, M., Barlogie, B., Shaughnessy, J. D., & Zhan, F. (2009) · Blood · doi:10.1182/blood-2008-12-194126 · Cited by 32
Lonial, S., & Cavenagh, J. D. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07649.x · Cited by 35
“…not eligible for high-dose therapy plus stem-cell transplantation (HDT–SCT) (Kyle et al, 2006; Wang et al, 2006) and in the transplant setting (Child et al, 2003; Cavo et al, 2007a; van de Velde et al, 2007; Lahuerta et al, 2008), and CR has recently been recommended as an additional…”
BackgroundMartino, M. V., Tripepi, G. L., Messina, G., Vincelli, I. D., Console, G., Recchia, A. G., Gentile, M., Molica, S., & Morabito, F. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.94 · Cited by 32
Ramzi, M., Zakerinia, M., Nourani, H., Dehghani, M., Vojdani, R., & Haghighinejad, H. (2011) · Clinical Transplantation · doi:10.1111/j.1399-0012.2011.01432.x · Cited by 36
Long-term outcome of patients with mutiple myeloma-related advanced renal failure following auto-SCT
Glavey, S. V., Gertz, M. A., Dispenzieri, A. A., Kumar, S. K., Buadi, F. K., Lacy, M. Q., Hayman, S. R., Dingli, D., McCurdy, A. B. R., Hogan, W. J., et al. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.109 · Cited by 34
Lévy, V., Katsahian, S., Fermand, J. P., Mary, J., & Chevret, S. (2005) · Medicine · doi:10.1097/01.md.0000173272.71949.a1 · Cited by 38
Miladinović, B., Mhaskar, R. S., Hozo, I., Kumar, A., Mahony, H., & Djulbegović, B. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.11.007 · Cited by 33
“This specific RRR has been used in well-designed published multiple myeloma RCTs [20,21] and in previously performed TSA [2,5].”
MethodThe Arkansas approach to therapy of patients with multiple myeloma
Barlogie, B., Anaissie, E. J., van Rhee, F., Pineda‐Roman, M., Zangari, M., Shaughnessy, J. D., Epstein, J., & Crowley, J. J. (2007) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2007.09.005 · Cited by 34
Ten Years of Improvement in the Management of Multiple Myeloma: 2000-2010
Harousseau, J. (2010) · Clinical Lymphoma Myeloma & Leukemia · doi:10.3816/clml.2010.n.076 · Cited by 36
Prinja, S., Kaur, G., Malhotra, P., Jyani, G., Ramachandran, R., Bahuguna, P., & Varma, S. C. (2017) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-017-0776-1 · Cited by 34
Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma
Auner, H. W., Garderet, L., & Kröger, N. M. (2015) · British Journal of Haematology · doi:10.1111/bjh.13608 · Cited by 32
“& Selby, P.J. (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.”
BackgroundDawson, M. A., Opat, S., Taouk, Y., Donovan, M., Zammit, M., Monaghan, K., Horvath, N., Roberts, A. W., Prince, H. M., Hertzberg, M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1022 · Cited by 32
“127x Bone marrow plasma cells (%), median (range) 55 (2-100) 62.”
BackgroundSecond Autologous Stem Cell Transplant: An Effective Therapy for Relapsed Multiple Myeloma
Abbi, K. K. S., Zheng, J., Devlin, S. M., Giralt, S., & Landau, H. J. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.11.677 · Cited by 35
“to progression after initial ASCT is 23 to 46 months and is longer for patients who receive post-transplant maintenance therapy [4-9].”
BackgroundDNA Damage Response in Multiple Myeloma: The Role of the Tumor Microenvironment
Saitoh, T., & Oda, T. (2021) · Cancers · doi:10.3390/cancers13030504 · Cited by 32
Song, M., Chung, J. S., Lee, J., Min, C., Ahn, J., Lee, S., Shin, D., Bae, S., Hong, J., Lee, G., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12820 · Cited by 31
Oakervee, H. E., Popat, R., & Cavenagh, J. D. (2007) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701540991 · Cited by 33
Gagliardi, F., Losa, M., Boari, N., Spina, A., Reni, M., Terreni, M. R., & Mortini, P. (2013) · Acta Neurochirurgica · doi:10.1007/s00701-013-1845-3 · Cited by 35
“25, 27, 28]; in that case a chemotherapy tailored on riskstratification is required with lenalidomide plus low-dose dexamethasone [36]; bortezomib, cyclophosphamide, dexamethasone [20]; bortezomib, lenalidomide, dexamethasone [20]; followed by autologous stem cell transplantation in eligible patients [9] and by mainte…”
BackgroundCheema, P. K., Zadeh, S., Kukreti, V., Reece, D. E., Chen, C. I., Trudel, S., & Mikhael, J. R. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.02.013 · Cited by 35
“EFS from diagnosis of MM has been reported at 27 to 32 months in patients\65 years of age that undergo upfront ASCT [15,16].”
BackgroundResultInfluentialLisenko, K., Pavel, P., Kriegsmann, M., Bruckner, T. M., Hillengaß, J., Goldschmidt, H., Witzens‐Harig, M., Ho, A. D., & Wuchter, P. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.12.631 · Cited by 33
Autologous Stem Cell Transplantation for Multiple Myeloma: Single Centre Experience from North India
Malhotra, P., Yanamandra, U., Khadwal, A., Prakash, G., Lad, D. P., Law, A., Khurana, H., Sachdeva, M., Bose, P., Das, R., et al. (2017) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-017-0876-y · Cited by 32
“A number of nonrandomized [3, 4], randomized [5, 6], and population-based studies [7] and meta-analyses [8, 9] have suggested that this approach is associated with improved response rates, and event-free survival (EFS) compared with conventional chemotherapy.”
BackgroundAggarwal, M., Agrawal, N., Yadav, N., Verma, P., Ahmed, R., Mehta, P., Kapoor, J., & Bhurani, D. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3370-1 · Cited by 34
Comparison of Twin and Autologous Transplants for Multiple Myeloma
Bashey, A., Pérez, W. S., Zhang, M., Anderson, K. C., Ballen, K. K., Berenson, J. R., To, L. B., Fonseca, R., Freytes, C. O., Gale, R. P., et al. (2008) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.07.007 · Cited by 33
Autologous stem cell transplantation beyond 60 years of age
Jantunen, E. (2006) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705514 · Cited by 35
Ailawadhi, S., Advani, P. P., Yang, D., Ghosh, R. N., Swaika, A., Roy, V., Foran, J. M., Colón‐Otero, G., & Chanan-Khan, A. A. (2015) · Cancer · doi:10.1002/cncr.29771 · Cited by 30
“In 1971, the National Cancer Act established the Cancer Centers Branch of the National Cancer Institute (NCI) and thereby formalized the establishment of NCI-designated cancer centers (CCs).8 The National Comprehensive Cancer Network (NCCN) represents an alliance of leading CCs that have the objective of improving qua…”
BackgroundInfluentialMarini, C., Maia, T., Bergantim, R., Pires, J. C., Aguiar, E. V., Guimarães, J. E., & Trigo, F. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3528-x · Cited by 32
Economic evaluation of plerixafor for stem cell mobilization.
Kymes, S. M., Pusic, I., Lambert, D. L., Gregory, M. H., Carson, K. R., & DiPersio, J. F. (2012) · PubMed · Cited by 30
Mølle, I., Peterslund, N. A., Thiel, S., & Steffensen, R. (2006) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705466 · Cited by 31
An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis
Sanchorawala, V., & Seldin, D. C. (2007) · Amyloid · doi:10.1080/13506120701613984 · Cited by 31
“High-dose intravenous melphalan chemotherapy and autologous peripheral blood stem cell transplantation has been successful in inducing complete hematologic remissions and prolonging survival in multiple myeloma [14,15].”
BackgroundYao, S., Hahn, T., Zhang, Y., Haven, D., Senneka, M. K., Dunford, L. M., Parsons, S. K., Confer, D. L., & McCarthy, P. L. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.06.014 · Cited by 30
Cure of myeloma: hype or reality?
Fassas, A., Shaughnessy, J. D., & Barlogie, B. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704757 · Cited by 31
Induction Therapy in Multiple Myeloma
Harousseau, J. (2008) · Hematology · doi:10.1182/asheducation-2008.1.306 · Cited by 32
“These results were fully confirmed by the larger trial published by the British Medical Research Council 7 years later.(2) As a consequence, until now, ASCT is considered standard of care as part of frontline therapy at least in younger patients (up to 65 years of age) with a normal renal function.”
ResultMcCarthy, H. O., Ottensmeier, C. H. H., Hamblin, T. J., & Stevenson, F. K. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04698.x · Cited by 31
“The high clinical responses achievable following autologous stem cell transplantation (ABSCT) in myeloma [42% partial remission, 44% complete remission (CR)] and relapsed nonHodgkin’s lymphoma (NHL) (RR 84%), make this an attractive platform for vaccination (Philip et al, 1995; Child et al, 2003).”
BackgroundNY-ESO-1 immunotherapy for multiple myeloma
Szmania, S. M., Tricot, G. J. K., & van Rhee, F. (2006) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190600742292 · Cited by 31
Bendamustine in multiple myeloma
Gentile, M., Vigna, E., Recchia, A. G., Morabito, L., Mendicino, F., Giagnuolo, G., & Morabito, F. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12609 · Cited by 32
“High-dose chemotherapy followed by ASCT represents an established therapy for young MM patients after first-line therapy (59, 60).”
BackgroundValproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma
Kitazoe, K.-I., Abe, M., Hiasa, M., Oda, A., Amou, H., Harada, T., Nakano, A., Takeuchi, K., Hashimoto, T., Ozaki, S., et al. (2008) · International Journal of Hematology · doi:10.1007/s12185-008-0226-9 · Cited by 29
“It is, however, an incurable disease, and the prognosis for elderly patients with MM has barely been improved, compared to younger patients treated with potent chemotherapeutic regimens including high-dose melphalan followed by autologous stem cell transplantation [ 1 , 2]. Therefore, the development of novel well-tol…”
ResultBaumann, P., Hagemeier, H., Mandl–Weber, S., Franke, D., & Schmidmaier, R. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328328d18b · Cited by 33
Recent advances in multiple myeloma: a Korean perspective
Hong, J., & Lee, J. H. (2016) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2015.408 · Cited by 31
“By increasing the dose intensity, it showed superior OS to conventional chemotherapy [22,23].”
BackgroundIs there still a role for stem cell transplantation in multiple myeloma?
Mina, R., & Lonial, S. (2019) · Cancer · doi:10.1002/cncr.32060 · Cited by 32
“apy and ASCT with standard-dose chemotherapy were conducted by the Intergroup Francophone du Myèlome (IFM) and the Medical Research Council (Table 1).(3,4)”
MethodKlepin, H. D., & Hurd, D. D. (2006) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705486 · Cited by 30
Uy, G. L., Goyal, S. D., Fisher, N. M., Oza, A. Y., Tomasson, M. H., Stockerl-Goldstein, K. E., DiPersio, J. F., & Vij, R. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.384 · Cited by 30
Christoforidou, A., Saliba, R. M., Williams, P. A. H., Qazilbash, M. H., Roden, L., Aleman, A., Weber, D., Mendoza, F. L., Podoloff, D. A., Wendt, R. E., et al. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2006.12.448 · Cited by 29
Trieu, Y., Trudel, S., Pond, G. R., Mikhael, J. R., Jaksic, W., Reece, D. E., Chen, C. I., & Stewart, A. K. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.12.1578 · Cited by 29
Outcome of unrelated transplants in patients with multiple myeloma
Ballen, K. K., King, R., Carston, M. J., Kollman, C., Nelson, G. O., Lim, S. H., Reece, D. E., Giralt, S., & Vesole, D. H. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704868 · Cited by 31
Clinical Impact of Bortezomib in Frontline Regimens for Patients with Multiple Myeloma
Manochakian, R., Miller, K. C., & Chanan-Khan, A. A. (2007) · The Oncologist · doi:10.1634/theoncologist.12-8-978 · Cited by 32
“Earlier studies demonstrated an overall survival (OS) and progression-free survival (PFS) benefit with HDT-SCT compared with conventional chemotherapy, plus higher overall response rates (ORRs; complete response [CR] plus partial response [PR]) and CR rates [5, 6 ]; with the use of novel combinations, both options see…”
BackgroundVogl, D. T., Stadtmauer, E. A., Richardson, P. G. G., Sonneveld, P., Schuster, M. W., Irwin, D. H., Facon, T. T. F., Harousseau, J., Boral, A. L., Neuwirth, R., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07875.x · Cited by 30
“Improvements in overall survival (OS) have been demonstrated with autologous stem cell transplantation (ASCT) (Attal et al, 1996; Child et al, 2003) and the novel agents thalidomide, bortezomib, and lenalidomide (Richardson et al, 2005; Dimopoulos et al, 2007; Facon et al, 2007; Weber et al, 2007).”
BackgroundAljitawi, O. S., Ganguly, S., Abhyankar, S., Ferree, M., Marks, R., Pipkin, J. D., & McGuirk, J. P. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.120 · Cited by 28
Fietz, T. J., Rieger, K., Dimeo, F., Blau, I. W., Thiel, E., & Knauf, W. U. (2004) · Journal of Clinical Apheresis · doi:10.1002/jca.20030 · Cited by 28
Metadata
- Authors
- Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J.
- Affiliations
- University of Leeds (GB)
- University of Birmingham (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-05-08
- Volume
- 348
- Issue
- 19
- Pages
- 1875-1883
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2102591890
- Semantic Scholar
- 5d90e1ff237e9db8f41e6e1e264450eed3f77e40
- Cited by
- 1,768
- References
- 23
- Citations by year
- 2026: 17 · 2025: 26 · 2024: 34 · 2023: 36 · 2022: 41 · 2021: 57 · 2020: 83 · 2019: 46 · 2018: 71 · 2017: 76 · 2016: 73 · 2015: 71 · 2014: 81 · 2013: 103 · 2012: 94
- FWCI
- 53.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- multiple myeloma, high-dose chemotherapy, autologous stem cell transplantation, first-line therapy, complete response, overall survival, progression-free survival, beta2-microglobulin, prognostic factors, previously untreated myeloma
- MeSH terms
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carmustine, Cause of Death, Combined Modality Therapy, Cyclophosphamide, Doxorubicin, Female, Humans, Male, Melphalan, Middle Aged, Multiple Myeloma, Prognosis, Survival Analysis, Hematopoietic Stem Cell Transplantation, Antineoplastic Agents, Alkylating
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.